| (AstraZeneca) D7984C00002 / GOG-3092 / eVOLVECervical | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Womenwith High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical) | Dr Nidhi Kumar-Tyagi | Open to recruitment | NCT06079671 |
| (ImmunoGen) IMGN853-0421 / GLORIOSA | Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second line platinum-based chemotherapy plus bevacizumab | Dr Nidhi Kumar-Tyagi | Suspended/On hold | NCT05445778 |
Find a Trial
Contact Us